In the realm of sleep medicine, the Apnea-Hypopnea Index (AHI)—a metric that counts how many times a patient stops breathing or breathes shallowly per hour—has long reigned supreme. It is the gold standard for diagnosis and the primary yardstick for measuring treatment efficacy. However, a growing coalition of sleep physicians and researchers is now challenging this narrow focus. They argue that for patients living with central sleep apnea (CSA) and co-occurring atrial fibrillation (AFib), the numbers on a sleep study report fail to capture the most critical reality: how the patient actually feels and functions in their daily life.
New, compelling evidence from a post-hoc analysis of the remēde System pivotal trial, recently published in the journal Sleep Medicine, suggests that treating CSA with transvenous phrenic nerve stimulation (TPNS) significantly improves quality of life and daytime alertness in patients battling the dual burden of CSA and AFib. As clinicians look toward more patient-centered models of care, this study provides a roadmap for integrating subjective patient experience into clinical decision-making.
The Overlap: A Hidden Comorbidity
The link between cardiovascular disease and sleep-disordered breathing is well-established, yet the intersection of CSA and AFib remains a critical, often underdiagnosed, blind spot in modern medicine. In the recent analysis, researchers evaluated 151 patients diagnosed with CSA and discovered that nearly 42% also suffered from atrial fibrillation.
This high prevalence is not merely a statistical curiosity; it represents a physiological feedback loop. Poor atrial function leads to elevated left atrial and pulmonary capillary pressures, which can trigger periodic breathing. Simultaneously, the sympathetic nervous system overactivity and hypoxemia inherent in CSA can exacerbate the burden of AFib, creating a vicious cycle of cardiac and respiratory decline.
Despite this, routine screening for sleep-disordered breathing among AFib patients is far from standard practice. Barriers such as fragmented healthcare systems, limited access to sleep laboratories, and an over-reliance on home sleep tests—which often struggle to differentiate between central and obstructive respiratory events—mean that many patients remain untreated, attributing their fatigue and breathlessness solely to their heart condition.
Chronology of Clinical Shift: From AHI to Patient-Centered Care
For decades, the trajectory of CSA treatment has been driven by the "correction" of respiratory indices. If the AHI dropped, the treatment was deemed a success. However, the patient’s journey often contradicted these clinical milestones.
- The Era of Physiological Focus: Historically, clinical trials were designed to demonstrate that devices like CPAP or adaptive servo-ventilation (ASV) could "fix" the breathing pattern. The primary endpoint was almost exclusively the reduction of the AHI.
- The Recognition of Symptom Disconnect: As patients began to report that they were still suffering from severe daytime fatigue despite "successful" therapy, researchers began to realize that the AHI was a flawed proxy for wellness.
- The Rise of TPNS: With the introduction of transvenous phrenic nerve stimulation, the industry began to explore not just the stabilization of breathing, but the systemic effects of the therapy on the autonomic nervous system.
- The Current Evidence: The recent Sleep Medicine publication marks a pivotal transition, focusing on patient-reported outcomes (PROs), such as the Epworth Sleepiness Scale and the Patient Global Assessment, to determine if the technology is truly improving the patient’s capacity to live a full life.
Supporting Data: The Impact of TPNS
The retrospective assessment, funded by ZOLL Respicardia Inc., focused on 64 participants who carried both a diagnosis of CSA and AFib. While the physiological data was undeniably impressive—with the median AHI falling from 49 to 21 events per hour and the central apnea index plummeting from 20 to just 1 event per hour—the researchers prioritized the subjective data.
The findings were striking:
- Daytime Alertness: Participants reported significant reductions in daytime sleepiness as measured by the Epworth Sleepiness Scale.
- Global Improvement: According to the Patient Global Assessment, participants felt a marked improvement in their overall condition compared to their baseline before the implantation of the TPNS system.
- Stability: The reduction in respiratory events correlated with a decrease in the "fight or flight" sympathetic response, suggesting that the therapy provides a more restorative sleep structure rather than just a mechanical correction of breathing.
These improvements are critical because, unlike CPAP, which has faced significant adherence issues in the CSA population, the implantable nature of TPNS ensures consistent delivery, which likely contributes to the sustained quality-of-life improvements observed by the study authors.
Official Responses and Expert Insights
Dr. Shahrokh Javaheri, a pulmonologist-sleep physician at the TriHealth-Bethesda North Sleep Center and co-author of the study, notes that the shift toward patient-centered metrics is overdue. "Patients typically seek treatment because they do not feel well," Dr. Javaheri explains. "A therapeutic option that could improve such symptoms is quite appealing to them and may also promote improved adherence to the therapy."
However, the medical community remains cautious about broad implementation. Dr. Muhammad Qasim, a specialist in pulmonary and respiratory medicine who was not involved in the study, highlights the complexity of the patient’s experience. "Limited awareness, fragmented care, sleep laboratory access, cost, and reliance on home tests that may not fully characterize central events all contribute to the barriers preventing evaluation," Dr. Qasim states.
Dr. Qasim advocates for a nuanced approach. While the findings are encouraging, he warns against universal screening for every AFib patient. Instead, he suggests a "high index of suspicion" for patients who present with persistent, unexplained fatigue or those who fail to respond to standard rhythm control therapies for their AFib.
Implications: The Future of Treatment Algorithms
The implications of this research for clinical practice are profound. First, it necessitates a change in how we distinguish between sleep disorders. Dr. Javaheri emphasizes that hypopneas are often misclassified as obstructive by default, leading to incorrect treatment plans. "It is increasingly important to confirm that the patient has CSA rather than OSA," he says, noting that this is vital when the AHI is composed primarily of hypopneas.
Second, the American Academy of Sleep Medicine (AASM) has updated its clinical practice guidelines to include TPNS as a recommended option for primary CSA and CSA due to heart failure. This is particularly relevant for patients who are intolerant to positive airway pressure (PAP) therapy.
Finally, the study forces us to redefine what "success" means in a clinical setting. As the researchers noted, if a patient’s primary goal is to be active enough to engage with family, a low AHI is irrelevant if the patient still feels exhausted. Success must now be measured as a multidimensional construct:
- Physiological: A reduction in apnea events and oxygen burden.
- Neurological: Improved sleep architecture and reduced sympathetic nervous system overactivity.
- Subjective: Higher scores on quality-of-life surveys and lower scores on sleepiness scales.
- Functional: The patient’s own self-reported ability to perform daily tasks.
The Path Forward: Unanswered Questions
Despite the positive findings, the medical community acknowledges that this is only the beginning. The next frontier in research is to bridge the gap between "feeling better" and "living longer."
Researchers are calling for adequately powered prospective trials to investigate whether treating CSA with TPNS can definitively reduce AFib burden, decrease the risk of stroke, lower hospitalization rates, and improve overall cardiovascular mortality. There is also a significant need to study the cognitive impact of these treatments and their effect on New York Heart Association functional classes.
For now, the message to clinicians is clear: listen to the patient. When treating complex patients with both heart and lung issues, the numbers on the screen are only part of the story. By educating patients on the full spectrum of available therapies—from CPAP and ASV to implantable TPNS—physicians can empower them to choose the path that not only manages their breathing but restores their quality of life. As the medical field continues to move toward personalized medicine, the integration of patient-reported outcomes will be the most significant indicator of progress in the fight against central sleep apnea.
